临床资料

合计(31例)

死亡(14例)

存活(17例)

P值

男性(例)

22 (71%)

9 (64.3%)

13 (76.5%)

0.693^a

发病年龄(岁)

64 (57, 68)

67 (59, 68)

60 (55, 66)

0.311^b

合并肿瘤

15 (48.4%)

12 (85.7%)

3 (17.6%)

<0.001^a

临床表现

癫痫发作

25 (80.6%)

12 (85.7%)

13 (76.5%)

0.664^a

癫痫持续状态

11 (35.5%)

6 (42.9%)

5 (33.3%)

0.477^a

认知障碍

21 (67.7%)

10 (71.4%)

11 (64.7%)

1.000^a

精神行为异常

11 (35.5%)

4 (28.6%)

7 (41.2%)

0.707^a

意识障碍

22 (71%)

12 (85.7%)

10 (58.8%)

0.132^a

运动障碍/不自主运动

4 (12.9%)

1 (7.1%)

3 (17.6%)

0.607^a

语言障碍

4 (12.9%)

2 (14.3%)

2 (11.8%)

1.000^a

睡眠障碍

9 (29%)

2 (14.3%)

7 (41.2%)

0.101^a

感染性发热

7 (22.6%)

6 (42.9%)

1 (5.9%)

0.028^a

脑电图异常

11 (35.5%)

5 (35.7%)

6 (35.3%)

1.000^a

脑MRI异常

15 (48.4%)

6 (42.9%)

9 (52.9%)

0.722^a

脑脊液压力增高

8 (27.6%)

3 (21.4%)

5 (33.3%)

0.682^a

脑脊液白细胞增高

21 (70%)

10 (71.4%)

11 (68.8%)

1.000^a

脑脊液抗体滴度

0.020^a

阴性

2 (6.5%)

2 (11.8%)

0 (0%)

0.138^a

+

12 (38.7%)

3 (21.4%)

9 (52.9%)

0.488^a

++

5 (16.1%)

5 (35.7%)

0 (0%)

0.012^a

+++

12 (38.7%)

6 (42.9%)

6 (35.5%)

0.724^a

血清抗体滴度

0.011^a

+

10 (32.3%)

1 (7.1%)

9 (52.9%)

0.009^a

++

9 (29%)

7 (50%)

2 (11.8%)

0.044^a

+++

12 (38.7%)

6 (42.9%)

6 (35.3%)

0.724^a

发病至免疫治疗的时间(天)

12 (9, 19)

10 (13, 17)

11 (6, 20)

0.973^c

激素冲击

26 (83.9%)

12 (85.7%)

14 (82.4%)

1.000^a

激素冲击 + IVIG

21 (67.7%)

8 (57.1%)

13 (76.5%)

0.441^a

免疫维持治疗时间(月)

5 (3, 7)

5.5 (3, 6)

4 (3, 7)

0.857^b